In 1980, polymorphic variance in the human genome was used to generate a first, physical map allowing monogenic traits to be traced to certain chromosomal regions. 1 Due to the recognition of fragment length polymorphisms (microsatellite markers) with several different alleles at the same chromosomal locus, single nucleotide polymorphisms (SNP) became neglected in this instance for a long time.
The obvious interindividual variability and the recognition that many cardiovascular parameters (e.g. blood pressure or ECG parameters) are continuous traits, raised the question of whether evident phenotypic differences in cardiovascular diseases and clinical outcome (e.g. in heart failure, myocardial infarction, or atrial fibrillation) have a common genetic component 2 either due to small size effects 3 or by multiple pathway interaction. 4 To date, many investigations addressing differences in the distribution of SNP alleles in cardiovascular diseases and controls have been triggered by the increasing, but still incomplete knowledge of genomic variance after whole-genome sequencing (3 × 10 9 nucleotide pairs, among them 1% protein coding) (Figures 1 and 2 ). Per individual there are (i) around 3.3 million SNP, but within the nearly 20 000 genes only a minority can be found (.10 000 non-synonymous and .10 000 synonymous SNP); 5, 6 and (ii) 250 -300 loss-of-function gene variants (including premature stops, splice site disruptions, and frameshifts); some might have been implicated in inherited disorders before and due to a germline mutation rate of 1 × 10 -8 up to 30 de novo mutations might be expected in the next generation. 6 Thus, the majority of SNP are located in intergenic regions of the human genome. For a long time, these non-coding sequences have been thought to be a 'gene desert' or a 'no man's land', since functional elements, e.g. those affecting gene expression or those involved in gene regulation, were largely unknown before the ENCODE (ENCyclopedia Of DNA Elements) Project was reported. 7 Of note, many structural changes [including short insertions or deletions (indels) as well as larger copy number variants up to several megabases] in non-coding sequences of the human genome are also known and differ extensively between individuals in a similar polymorphic manner, e.g. as shown for several hundreds of thousands indels. 6, 8 Due to improved RNA sequencing technologies, nucleotide variation at these functional genomic elements will be further linked to changes in transcript sequence and tissue-specific transcriptional profiles. 9 How can this genome information be used in cardiovascular medicine, in particular for explaining sudden cardiac death (SCD) susceptibility? In industrial countries, SCD is a substantial health issue, and affects worldwide 4-5 million cases per year, thereby 20% of the total mortality. Often, and especially in youths and young adults, there is a clear monogenic component due to the presence of an inherited arrhythmia syndrome or cardiomyopathy. Since these entities are genetically quite heterogeneous (5 -25 causative genes per disease) and mutation detection rates (genetic testing sensitivity) range from 10-80%, modern technologies such as next-generation sequencing (NGS) are being applied more and more. 10 With the exception of hypertrophic cardiomyopathy (HCM), these conditions are considered as rare diseases (prevalence ,1 : 2000) and patient care and genetic testing are recommended to be facilitated in specialized centres. But what about the common and mainly polygenic conditions causing SCD, e.g. coronary artery disease (CAD; linked to 80% of SCD), and where first-degree relatives of an SCD victim still have a higher rate for SCD (after adjustment for risk factors) than individuals with a negative family history? 11 In this issue of the journal, Hernesniemi and co-workers present a comprehensive study in which they developed a weighted genetic (better: genomic) risk score (GRS) for CAD and occurrence of SCD. 12 A key hurdle for the associating SNP alleles with a certain phenotype is that the majority of 'harmful' SNP alleles will only have a small phenotypic effect
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size that may be countered by other, co-existing SNP alleles with 'beneficial effects'. A GRS now summarizes (or counts) the risk-associated variation across selected SNP loci (n ¼ 153 referring to GRS CAD ; all SNP were strongly associated with CAD, as reported by the CARDIoGRAMplusC4D Consortium); in addition, the authors weighted each SNP risk allele by applying specific risk coefficients, and calculations were subsequently adjusted with clinical (risk) factors. Therefore, a GRS for CAD and/or SCD might be an efficient and effective means of assessing risk measurement, independently from the Framingham Risk Score (FRS) that incorporates factors other than just genetic factors (the patient's age, gender, cholesterol levels, smoking and diabetic status, and blood pressure) to predict a 10-year risk for CAD. The authors could uniquely use DNA samples and clinical as well as pathological information from three autopsy series in Finland (1035 autopsy samples including 306 of SCD due to CAD). The allele frequencies of some SNP alleles might be overestimated, since the Finnish population is genetically isolated to some degree and subjected to a lower population admixture. 13 To have access to such an outstanding sample collection is quite impressive and refers to the fact that in Finland medico legal autopsy is mandatory whenever a sudden death is not due to a known cause. Thus, the authors reported that GRS CAD was capable of differentiating between SCD victims in the presence of CAD or not, depending on the numbers of risk alleles.
Next, these results were tested in a prospective study of 2321 CAD patients (FINCAVAS) including 48 in whom all-cause death occurred during follow-up (among them 31 with proven CAD). 
Editorial
Regarding the low number of SCD, the GRS SCD only weakly associated with prospective SCD in the setting of CAD. Finally, 13 out of the 153 SNP were proposed to correlate with SCD due to CAD and it has been concluded that SNP array-based genetic testing may provide a cost-efficient, safe, and easy alternative for SCD risk stratification in the setting of CAD. Will genetic testing of multiple SNP alleles influence clinical decision-making, e.g. towards an effective prevention of SCD and, thereby, an early ICD implantation? Probably not, in particular as a single or exclusive argument in the setting of SCD prevention. From the experience of two decades of understanding the genetic basis of inherited arrhythmia syndromes, it became quite clear that even among carriers of an identical mutation (e.g. in one of the cardiac ion channel genes), the clinical expression (phenotype) is still unexpectedly variable and inhomogeneous. As a consequence, treatment recommendation and strength are based on an individual basis and on clinical criteria; thus, not all mutation carriers will be treated automatically by a device, even if one sudden or survived cardiac arrest occurred in an affected relative with the same mutation. In comparison with a single SNP, the effect size of bona fide mutations is stronger, and incomplete penetrance, i.e. mutation carriers without clinical signs of the disease, only occurs in 5-20%. 14 Nevertheless, systematic investigations of candidate or genomewide SNP [.700 000 SNP; a so-called genome-wide association study (GWAS)], together with sufficient numbers of matched cases and controls have led to many powerful reports for common cardiovascular traits such as CAD 15 -17 or myocardial infarction, 17 ventricular fibrillation during myocardial infarction, 18 blood pressure, 19, 20 atrial fibrillation, cerebral stroke, or quantitative trait loci (QTL) for distinct ECG parameters 21 -24 or pharmacogenomic drug -gene interactions. 25 As exemplified for CAD and by Hernesniemi and co-workers in this issue of the journal, it is likely that genotyping of a single SNP locus for assessment of risk modulation is not powerful, and thereby is not sufficient to be used in clinical practice; thus, the generation of genetic (better: genomic) risk scores (GRS) is the right step forward to use complex information in a prospective clinical context and for personalized or precision medicine. However, GRS will be only an addendum for already established CAD risk parameters, but may be further considered on an individual patient basis (e.g. 'low-risk vs. high-risk CAD') and dependent on the physician's experience. So far, the majority of SNP loci are only linked by population association with CAD or SCD, but the functional link (the 'missing heritability') often remains elusive. 26 However, as also seen in other multifactorial diseases, most of the genetic variants associated with CAD, ECG parameters, or even SCD directly occur in non-coding sequences, within introns of genes or in intergenic regions, and only in very few cases is the biological impact of these variants on the related phenotype known. As long as we do not understand why a common genetic variant may predispose for a given phenotype, several independent and confirming sample cohorts (of different ethnicity) have to be investigated before such an SNP can be offered as a useful genetic test. In addition to network and bioinformatic approaches, the comprehensive integration of 'omics' data will be a clue for understanding genomic prediction and individual variation in the light of SNP. Here, the systematic study of SNP at non-coding, but nearby gene regulatory sites or of distant, intergenic sites (e.g. for transcription factor binding) that might affect both mRNA expression and mRNA splicing will be of high scientific impact in the future to prove whether genomic variation has a functional consequence. More and more of these eQTL (expressed QTL) are being identified 27 and are in the process of being proven as a functional link between genomic variation and gene expression at a site, with particular emphasis on cardiovascular tissues.
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